Sonostar Ventures

Sonostar Ventures is a private equity and venture capital firm based in Chappaqua, New York, specializing in early-stage and PIPE investments. Founded in July 2005, the firm focuses on companies capable of generating $100 million or more in revenue within four years, targeting annualized returns of at least 40 percent over a four to five-year horizon. Sonostar typically invests between $1.5 million and $3 million, with the potential to facilitate additional financing when necessary. The firm has a collaborative structure, with its members—successful professionals from diverse fields—sharing investment ideas, deal flow, and insights, which enhances their investment strategy. Sonostar Ventures also seeks to take active roles in the management of its portfolio companies by securing positions on their Boards of Directors or Advisory Boards. The firm's investment interests span various sectors, including biotechnology, information technology, and e-commerce, among others.

Greg Kiernan

President and CEO

James Kiernan

Managing Director

2 past transactions

Andie

Seed Round in 2018
Andie Co. is an online retailer specializing in women's swimwear, particularly known for its designer-quality one-piece swimsuits. Founded in 2016 and based in New York, the company operates as a direct-to-consumer brand, allowing customers to purchase swimwear directly through its eCommerce platform. By eliminating retail middlemen, Andie provides high-design, luxurious swimsuits at accessible prices, enabling women to try on their selections at home to find the best fit. In addition to swimsuits, Andie also offers accessories and gift cards, positioning itself as a compelling alternative within the swimwear market.

Tigris Pharmaceuticals

Series C in 2010
Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.